Ocugen Inc
(NAS:OCGN)
$
1.27
-0.11 (-7.97%)
Market Cap: 326.84 Mil
Enterprise Value: 335.61 Mil
PE Ratio: 0
PB Ratio: 10.58
GF Score: 34/100 - Q1 2024 Ocugen Inc Earnings Call TranscriptMay 14, 2024$1.7 (-6.08%)Earnings
- Q4 2023 Ocugen Inc Earnings Call TranscriptApr 02, 2024$1.38 (-10.39%)Earnings
- Q3 2023 Ocugen Inc Earnings Call TranscriptNov 09, 2023$0.3685 (-4.11%)Earnings
- Ocugen Inc at Chardan Genetic Medicines Conference TranscriptOct 02, 2023
- Ocugen Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Ocugen Inc to Discuss Updated Results from the Phase 1/2 Trial of OCU400 Investor Call TranscriptSep 13, 2023
- Q2 2023 Ocugen Inc Earnings Call TranscriptAug 22, 2023$0.4032 (-8.96%)Earnings
- Ocugen Inc Annual Shareholders Meeting TranscriptJun 23, 2023
- Q1 2023 Ocugen Inc Earnings Call TranscriptMay 05, 2023$0.7 (+0.72%)Earnings
- Ocugen Inc at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Ocugen Inc To Host Virtual Investor & Analyst Event TranscriptApr 14, 2023
- Ocugen Inc at ROTH Conference TranscriptMar 13, 2023
- Q4 2022 Ocugen Inc Earnings Call TranscriptFeb 28, 2023$0.9962 (+2.07%)Earnings
- Q3 2022 Ocugen Inc Earnings Call TranscriptNov 08, 2022$1.64 (+7.19%)Earnings
- Ocugen Inc at Chardan Genetic Medicines Conference TranscriptOct 04, 2022
- Ocugen Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Ocugen Inc at H C Wainwright Ophthalmology Virtual Conference TranscriptAug 17, 2022
- Q2 2022 Ocugen Inc Earnings Call TranscriptAug 05, 2022$2.86 (+3.25%)Earnings
- Ocugen Inc Annual Shareholders Meeting TranscriptJun 07, 2022
- Q1 2022 Ocugen Inc Earnings Call TranscriptMay 06, 2022$2.16 (-5.26%)Earnings
- Q4 2021 Ocugen Inc Earnings Call TranscriptFeb 25, 2022$3.22 (+5.40%)Earnings
- Q3 2021 Ocugen Inc Earnings Call TranscriptNov 09, 2021$8.92 (-7.37%)Earnings
- Ocugen Inc at Citi BioPharma Conference (Virtual) TranscriptSep 08, 2021
- Q2 2021 Ocugen Inc Earnings Call TranscriptAug 06, 2021$7.86 (+4.94%)Earnings
- Q1 2021 Ocugen Inc Earnings Call TranscriptMay 07, 2021$9.19 (-4.12%)Earnings
- Q4 2020 Ocugen Inc Earnings Call TranscriptMar 18, 2021$8.9 (-6.81%)Earnings
- Ocugen Inc at Noble Financial Small & Microcap Investor Conference (Virtual) TranscriptJan 20, 2021
- Ocugen Inc at Commercializing Transformative Therapies for Blindness Diseases TranscriptNov 10, 2020
- Ocugen Inc at NAI Interactive GCFF Virtual Conference -- Diversified Investing Strategies TranscriptNov 05, 2020
- Ocugen Inc at LD 500 Conference (Virtual) TranscriptSep 04, 2020
- Q2 2020 Ocugen Inc Earnings Call TranscriptAug 14, 2020$0.5648 (-9.34%)Earnings
- Q4 2019 Ocugen Inc Earnings Call TranscriptMar 27, 2020$0.2999 (-14.31%)Earnings
- Histogenics Corp and Ocugen Inc to Discuss the Merger Agreement TranscriptApr 08, 2019
Ocugen Inc at ROTH Conference Transcript
Mar 13, 2023 / 04:00PM GMT
Release Date Price:
$0.9095
(-1.60%)
Jonathan Aschoff
ROTH Capital Partners, LLC - Analyst
I'm Jonathan Aschoff, senior biotechnology analyst at ROTH MKM; and with us now is Shankar Musunuri, the CEO of Ocugen. And hello, Shankar. Welcome.
Shankar Musunuri
Ocugen, Inc. - Chairman of the Board, CEO, & Co-Founder
Thank you. Thank you, Jonathan. Thank you for having me.
Questions & Answers
Jonathan Aschoff
ROTH Capital Partners, LLC - Analyst
It's great to have you. So your company has had a diversified portfolio, gene therapy, cell therapy, biologics, vaccine. You're running the whole gamut here. How did that happen, and what are some unifying characteristics you can tell us that have led to that?
Shankar Musunuri
Ocugen, Inc. - Chairman of the Board, CEO, & Co-Founder
Yeah. You have, starting with the shared science, you take gene therapies and vaccines with their novel vectors, there are a lot of commonalities. And there is also manufacturing change platform with a lot of similarities.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)